







an Open Access Journal by MDPI

Equine Infectious Diseases and Immunotherapy

Guest Editors:

Dr. Pompei Florin Bolfa

Department of Biomedical Sciences, Ross University, Iselin, NJ, USA

Dr. Caroline Leroux

Viral Infections and Comparative Pathology, University Claude Bernard Lyon 1, 69100 Villeurbanne, France

Deadline for manuscript submissions:

closed (31 December 2021)

Message from the Guest Editors

Infectious diseases in equines, whether endemic, emerging or reemerging in a population, represent constant challenges to veterinarians and owners. These diseases may result in a burden to equine practices and hospitals. which are constantly on the lookout for newer costeffective diagnostic tools, therapeutic approaches, prevention strategies, or efficient epidemiological surveillance. Clinical problems can be puzzling, and this Special Issue of Vaccines aims to bring together recent knowledge on viral, bacterial, rickettsial, fungal, and parasitic diseases in equines to better understand their pathogenesis, improve therapy, and implement relevant control measures. Allergies in horses are not currently fully understood, but recent advances in immunotherapy approaches are encouraging.













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with <u>article processing charges (APC)</u> paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Contact Us